Zogenix Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 327

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.9B

Zogenix General Information

Description

Developer of therapeutic drugs and medicines intended to improve the lives of patients suffering from rare diseases. The company focuses on developing and commercializing treatments for central nervous system disorders and epilepsy, thereby addressing significant unmet medical needs.

Contact Information

Website
www.zogenix.com
Formerly Known As
SJ2Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 5959 Horton Street
  • Fifth Floor
  • Emeryville, CA 94608
  • United States
Primary Industry
Drug Discovery
Acquirer
Corporate Office
  • 5959 Horton Street
  • Fifth Floor
  • Emeryville, CA 94608
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zogenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Merger/Acquisition 07-Mar-2022 $1.9B Completed Generating Revenue
13. Secondary Transaction - Open Market Completed Generating Revenue
12. Secondary Transaction - Open Market Completed Generating Revenue
11. Debt - General 16-Jun-2016 Completed Generating Revenue
10. Secondary Transaction - Open Market 01-Dec-2015 Completed Generating Revenue
9. 2PO 29-Jul-2015 Completed Generating Revenue
8. 2PO 05-Nov-2013 Completed Clinical Trials - Phase 3
7. 2PO 15-Sep-2011 Completed Clinical Trials - Phase 3
6. IPO 23-Nov-2010 $56M $245M Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C) 14-Jul-2010 $50M $189M Completed Startup
To view Zogenix’s complete valuation and funding history, request access »

Zogenix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic drugs and medicines intended to improve the lives of patients suffering from rare diseases. The
Drug Discovery
Emeryville, CA
327 As of 2021

Louisville, KY
 

Solana Beach, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zogenix Competitors (45)

One of Zogenix’s 45 competitors is US WorldMeds, a Formerly VC-backed company based in Louisville, KY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
US WorldMeds Formerly VC-backed Louisville, KY
Sentynl Therapeutics Formerly PE-Backed Solana Beach, CA
Johnson&Johnson Innovative Medicine Venture Capital-Backed Raritan, NJ
Ethypharm Private Equity-Backed Saint Cloud, France
Attune Pharmaceuticals Venture Capital-Backed New York, NY
You’re viewing 5 of 45 competitors. Get the full list »

Zogenix Patents

Zogenix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3222484-A1 Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools Pending 18-Jun-2021
CA-3209159-A1 Aqueous solutions containing purines and pyrimidines and uses thereof Pending 26-Mar-2021
CA-3150755-A1 Polymorphic forms of deoxycytidine, compositions comprising the same and uses Pending 19-Aug-2019
CA-3096264-A1 Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools Pending 12-Apr-2018
WO-2016137665-A1 Needle-free injectors comprising sound suppression Inactive 27-Feb-2015 A61M5/30
To view Zogenix’s complete patent history, request access »

Zogenix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zogenix Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abingworth Venture Capital Minority
Avoro Capital Venture Capital Minority
Chicago Growth Partners PE/Buyout Minority
Domain Associates Venture Capital Minority
Great Point Partners PE/Buyout Minority
You’re viewing 5 of 12 investors. Get the full list »

Zogenix Investments & Acquisitions (3)

Zogenix’s most recent deal was a Corporate with Tevard Biosciences for . The deal was made on 03-Dec-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tevard Biosciences 03-Dec-2020 Corporate Drug Discovery
Modis Therapeutics 09-Sep-2019 Merger/Acquisition Drug Discovery
Brabant Pharma 27-Oct-2014 Merger/Acquisition Drug Delivery
To view Zogenix’s complete investments and acquisitions history, request access »

Zogenix ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

15.3 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Zogenix’s complete esg history, request access »

Zogenix FAQs

  • When was Zogenix founded?

    Zogenix was founded in 2006.

  • Where is Zogenix headquartered?

    Zogenix is headquartered in Emeryville, CA.

  • What is the size of Zogenix?

    Zogenix has 327 total employees.

  • What industry is Zogenix in?

    Zogenix’s primary industry is Drug Discovery.

  • Is Zogenix a private or public company?

    Zogenix is a Private company.

  • What is the current valuation of Zogenix?

    The current valuation of Zogenix is .

  • What is Zogenix’s current revenue?

    The current revenue for Zogenix is .

  • How much funding has Zogenix raised over time?

    Zogenix has raised $465M.

  • Who are Zogenix’s investors?

    Abingworth, Avoro Capital, Chicago Growth Partners, Domain Associates, and Great Point Partners are 5 of 12 investors who have invested in Zogenix.

  • Who are Zogenix’s competitors?

    US WorldMeds, Sentynl Therapeutics, Johnson&Johnson Innovative Medicine, Ethypharm, and Attune Pharmaceuticals are some of the 45 competitors of Zogenix.

  • When was Zogenix acquired?

    Zogenix was acquired on 07-Mar-2022.

  • Who acquired Zogenix?

    Zogenix was acquired by UCB.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process